



ALPHA COGNITION ANNOUNCES ENGAGEMENT OF INVESTOR RELATIONS SERVICE PROVIDER

Vancouver, BC – July 18, 2024 – Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a pre-commercial, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, today announced that it has engaged Stonegate Capital Partners, Inc. (“Stonegate”) to enhance the Company’s investor relations strategy by raising awareness of the Company and its business prospects with a focus on a U.S. investor audience.

The agreement with Stonegate provides for payment of a monthly fee of US\$5,000 for an extendable six-month term based on an effective date of July 9, 2024. The fee may be reduced to US\$2,500 per month in conjunction with a reduction in the scope of services at the Company’s option. Following the initial six month term, the agreement may be terminated by either party on five days’ notice.

Stonegate specializes in institutional targeting and investor outreach for publicly traded companies, providing access to institutional relationships and experience creating a platform for companies seeking to expand their investor relationships and shareholder base. Stonegate’s team is made up of investment bankers, research analysts, institutional salesman and industry experts, and its services are complementary to existing investor relations initiatives. Stonegate operates as an arm’s length service provider to the Company, holds no securities of the Company, and is not entitled to receive any securities of the Company in connection with this engagement. Stonegate has a business address at 500 Crescent Court, Suite 370, Dallas, TX 75201 and Stonegate can be contacted at: info@stonegateinc.com and 214-987-4121.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a pre-commercial, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease following the recent New Drug Application submission and acceptance by the U.S. Food and Drug Administration.

ALPHA-1062, is a patented new innovative product being developed as a next generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is in pre-clinical development in combination with memantine to treat moderate to severe Alzheimer’s disease, in pre-clinical development with sublingual formulation for patients suffering from dysphagia and is intended to be out-licensed for pre-clinical development to study an intranasal formulation for cognitive impairment with mTBI (otherwise known as concussion).



For further information:

Michael McFadden, CEO
Tel: 1-858-344-4375
info@alphacognition.com
<https://www.alphacognition.com>

Forward-looking Statements

Certain information contained herein constitutes “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to Stonegate’s services and term of engagement. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Such forward looking statements include statements regarding the potential benefits of ALPHA-1062. Such statements, and other forward-looking statements herein, are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.